Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:hematologic agent
go back to main search page
Accession:CHEBI:50248 term browser browse the term
Definition:Drug that acts on blood and blood-forming organs and those that affect the hemostatic system.
Synonyms:related_synonym: hematologic agents


show annotations for term's descendants           Sort by:
 
acetylsalicylic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G HSPA5 heat shock protein family A (Hsp70) member 5 multiple interactions EXP Aspirin inhibits the reaction [Hydrogen Peroxide results in increased expression of HSPA5 protein] CTD PMID:20665602 NCBI chr 1:265,930,044...265,934,959
Ensembl chr 1:265,930,045...265,934,904
JBrowse link
G PLA2G1B phospholipase A2 group IB multiple interactions EXP Aspirin promotes the reaction [PLA2G1B protein results in increased expression of PTGS2 mRNA] CTD PMID:10706128 NCBI chr14:40,314,520...40,322,315
Ensembl chr14:40,314,444...40,322,319
JBrowse link
G PTGS2 prostaglandin-endoperoxide synthase 2 multiple interactions EXP Aspirin promotes the reaction [PLA2G1B protein results in increased expression of PTGS2 mRNA] CTD PMID:10706128 NCBI chr 9:127,850,164...127,858,866
Ensembl chr 9:127,850,013...127,858,884
JBrowse link
dermatan sulfate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G FGF10 fibroblast growth factor 10 affects binding EXP [Chondroitin Sulfates binds to Dermatan Sulfate] which binds to FGF10 protein CTD PMID:14699094 NCBI chr16:28,695,465...28,779,953
Ensembl chr16:28,695,469...28,777,541
JBrowse link
G FGF18 fibroblast growth factor 18 affects binding EXP [Chondroitin Sulfates binds to Dermatan Sulfate] which binds to FGF18 protein CTD PMID:14699094 NCBI chr16:52,724,867...52,760,246
Ensembl chr16:52,725,356...52,760,236
JBrowse link
G FGF2 fibroblast growth factor 2 affects binding EXP [Chondroitin Sulfates binds to Dermatan Sulfate] which binds to FGF2 protein CTD PMID:14699094 NCBI chr 8:101,278,877...101,344,084
Ensembl chr 8:101,278,878...101,343,916
JBrowse link
G MDK midkine affects binding EXP [Chondroitin Sulfates binds to Dermatan Sulfate] which binds to MDK protein CTD PMID:14699094 NCBI chr 2:16,130,787...16,133,791
Ensembl chr 2:16,130,782...16,133,510
JBrowse link
G PTN pleiotrophin affects binding EXP [Chondroitin Sulfates binds to Dermatan Sulfate] which binds to PTN protein CTD PMID:14699094 NCBI chr18:12,219,708...12,309,045
Ensembl chr18:12,219,790...12,311,922
JBrowse link
dextran sulfate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CASP1 caspase 1, apoptosis-related cysteine peptidase multiple interactions
increases expression
EXP [Dextran Sulfate co-treated with Zearalenone] results in increased expression of CASP1 mRNA; [Dextran Sulfate co-treated with Zearalenone] results in increased expression of CASP1 protein; Zearalenone inhibits the reaction [Dextran Sulfate results in increased expression of CASP1 mRNA]
Dextran Sulfate results in increased expression of CASP1 mRNA; Dextran Sulfate results in increased expression of CASP1 protein
CTD PMID:30270565 NCBI chr 9:35,188,066...35,199,364
Ensembl chr 9:35,186,420...35,200,328
JBrowse link
G IL18 interleukin 18 increases expression
multiple interactions
EXP Dextran Sulfate results in increased expression of IL18 mRNA
[Dextran Sulfate co-treated with Zearalenone] results in increased expression of IL18 mRNA; Dextran Sulfate inhibits the reaction [Zearalenone results in increased expression of IL18 mRNA]; Zearalenone inhibits the reaction [Dextran Sulfate results in increased expression of IL18 mRNA]
CTD PMID:30270565 NCBI chr 9:39,839,959...39,861,258
Ensembl chr 9:39,834,966...39,873,300
JBrowse link
G LOC100522011 apoptosis-associated speck-like protein containing a CARD multiple interactions
increases expression
EXP [Dextran Sulfate co-treated with Zearalenone] results in increased expression of PYCARD mRNA; [Dextran Sulfate co-treated with Zearalenone] results in increased expression of PYCARD protein
Dextran Sulfate results in increased expression of PYCARD mRNA; Dextran Sulfate results in increased expression of PYCARD protein
CTD PMID:30270565 NCBI chr 3:17,305,921...17,307,521
Ensembl chr 3:17,306,179...17,307,512
JBrowse link
G LOC110258578 interleukin-1 beta-like multiple interactions
increases expression
EXP [Dextran Sulfate co-treated with Zearalenone] results in increased expression of IL1B mRNA; Dextran Sulfate inhibits the reaction [Zearalenone results in increased expression of IL1B mRNA]; Zearalenone inhibits the reaction [Dextran Sulfate results in increased expression of IL1B mRNA] CTD PMID:30270565
G NLRP3 NLR family pyrin domain containing 3 multiple interactions
increases expression
EXP [Dextran Sulfate co-treated with Zearalenone] results in increased expression of NLRP3 mRNA; [Dextran Sulfate co-treated with Zearalenone] results in increased expression of NLRP3 protein; Dextran Sulfate inhibits the reaction [Zearalenone results in increased expression of NLRP3 mRNA]; Zearalenone inhibits the reaction [Dextran Sulfate results in increased expression of NLRP3 mRNA]; Zearalenone inhibits the reaction [Dextran Sulfate results in increased expression of NLRP3 protein]
Dextran Sulfate results in increased expression of NLRP3 mRNA; Dextran Sulfate results in increased expression of NLRP3 protein
CTD PMID:30270565 NCBI chr 2:56,892,241...56,977,412
Ensembl chr 2:56,892,242...56,977,234
JBrowse link
dicoumarol term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G NQO1 NAD(P)H quinone dehydrogenase 1 multiple interactions EXP Dicumarol inhibits the reaction [sulforafan inhibits the reaction [Cisplatin results in decreased activity of NQO1 protein]] CTD PMID:20732396 NCBI chr 6:17,292,962...17,302,593
Ensembl chr 6:17,292,769...17,302,590
JBrowse link
ethylenediaminetetraacetic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ANPEP alanyl aminopeptidase, membrane multiple interactions EXP Edetic Acid promotes the reaction [1,10-phenanthroline results in decreased activity of ANPEP protein] CTD PMID:17109655 NCBI chr 7:55,351,081...55,373,856
Ensembl chr 7:55,351,083...55,373,881
JBrowse link
G LTA4H leukotriene A4 hydrolase decreases activity EXP Edetic Acid results in decreased activity of LTA4H protein CTD PMID:21670530 NCBI chr 5:87,486,552...87,518,520
Ensembl chr 5:87,486,512...87,518,515
JBrowse link
heparin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G PSP-I porcine seminal protein I multiple interactions EXP zinc chloride promotes the reaction [PSP-I protein binds to Heparin]; Zinc promotes the reaction [PSP-I protein binds to Heparin] CTD PMID:16819821 NCBI chr14:132,302,376...132,309,388
Ensembl chr14:132,274,241...132,320,855
JBrowse link
S-nitrosoglutathione term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G AKT1 AKT serine/threonine kinase 1 multiple interactions EXP AKT1 protein mutant form inhibits the reaction [S-Nitrosoglutathione results in increased expression of HIF1A protein] CTD PMID:11514583
G HIF1A hypoxia inducible factor 1 subunit alpha multiple interactions
increases expression
EXP 2,3-dimethoxy-1,4-naphthoquinone inhibits the reaction [S-Nitrosoglutathione results in increased expression of HIF1A protein]; AKT1 protein mutant form inhibits the reaction [S-Nitrosoglutathione results in increased expression of HIF1A protein]; Genistein inhibits the reaction [S-Nitrosoglutathione results in increased expression of HIF1A protein]; PIK3R1 protein mutant form inhibits the reaction [S-Nitrosoglutathione results in increased expression of HIF1A protein]; Wortmannin inhibits the reaction [S-Nitrosoglutathione results in increased expression of HIF1A protein] CTD PMID:11514583 NCBI chr 1:190,625,436...190,673,926
Ensembl chr 1:190,625,181...190,674,850
JBrowse link
G PIK3R1 phosphoinositide-3-kinase regulatory subunit 1 multiple interactions EXP PIK3R1 protein mutant form inhibits the reaction [S-Nitrosoglutathione results in increased expression of HIF1A protein] CTD PMID:11514583 NCBI chr16:46,434,757...46,523,626
Ensembl chr16:46,434,873...46,523,609
JBrowse link
troglitazone term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ABCA1 ATP binding cassette subfamily A member 1 decreases expression
affects localization
EXP Troglitazone results in decreased expression of ABCA1 mRNA
Troglitazone affects the localization of ABCA1 protein
CTD PMID:16530456 NCBI chr 1:246,144,277...246,278,492
Ensembl chr 1:246,144,277...246,278,492
JBrowse link
G APOA1 apolipoprotein A1 increases secretion
decreases expression
multiple interactions
EXP Troglitazone results in increased secretion of APOA1 protein
Troglitazone results in decreased expression of APOA1 mRNA
Troglitazone promotes the reaction [APOA1 protein results in increased transport of Cholesterol]
CTD PMID:16530456 NCBI chr 9:44,216,481...44,218,360
Ensembl chr 9:44,216,393...44,218,978
JBrowse link
G CASP3 caspase 3 multiple interactions EXP [Troglitazone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of CASP3 mRNA CTD PMID:30481989 NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,749...45,763,773
JBrowse link
G CEBPA CCAAT enhancer binding protein alpha increases expression
multiple interactions
EXP Troglitazone results in increased expression of CEBPA mRNA
Troglitazone promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of CEBPA mRNA]
CTD PMID:11225715, PMID:30481989 NCBI chr 6:43,083,200...43,085,884
Ensembl chr 6:43,083,203...43,085,836
JBrowse link
G CTNNB1 catenin beta 1 multiple interactions EXP Troglitazone promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of CTNNB1 mRNA] CTD PMID:30481989 NCBI chr13:25,163,550...25,208,314
Ensembl chr13:25,137,173...25,208,311
JBrowse link
G CYP17A1 cytochrome P450 17A1 multiple interactions EXP Troglitazone inhibits the reaction [[LHB protein co-treated with INS protein] results in increased expression of CYP17A1 mRNA]; Troglitazone inhibits the reaction [[LHB protein co-treated with INS protein] results in increased expression of CYP17A1 protein modified form] CTD PMID:11889176 NCBI chr14:113,805,616...113,820,445
Ensembl chr14:113,805,611...113,812,041
JBrowse link
G FABP4 fatty acid binding protein 4, adipocyte multiple interactions EXP Troglitazone promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of FABP4 mRNA] CTD PMID:30481989 NCBI chr 4:55,096,400...55,101,209
Ensembl chr 4:55,096,404...55,101,897
JBrowse link
G IGF1 insulin like growth factor 1 multiple interactions EXP Troglitazone promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of IGF1 mRNA] CTD PMID:30481989 NCBI chr 5:81,762,027...81,909,253
Ensembl chr 5:81,775,970...81,848,037
JBrowse link
G IGF1R insulin like growth factor 1 receptor multiple interactions EXP Troglitazone promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of IGF1R mRNA] CTD PMID:30481989 NCBI chr 1:137,383,623...137,691,038
Ensembl chr 1:137,387,925...137,690,666
JBrowse link
G INS insulin multiple interactions EXP Troglitazone inhibits the reaction [[LHB protein co-treated with INS protein] results in increased abundance of Androstenedione]; Troglitazone inhibits the reaction [[LHB protein co-treated with INS protein] results in increased abundance of Testosterone]; Troglitazone inhibits the reaction [[LHB protein co-treated with INS protein] results in increased expression of CYP17A1 mRNA]; Troglitazone inhibits the reaction [[LHB protein co-treated with INS protein] results in increased expression of CYP17A1 protein modified form] CTD PMID:11889176 NCBI chr 2:1,496,842...1,498,052
Ensembl chr 2:1,496,842...1,497,841
JBrowse link
G LHB luteinizing hormone subunit beta multiple interactions EXP Troglitazone inhibits the reaction [[LHB protein co-treated with INS protein] results in increased abundance of Androstenedione]; Troglitazone inhibits the reaction [[LHB protein co-treated with INS protein] results in increased abundance of Testosterone]; Troglitazone inhibits the reaction [[LHB protein co-treated with INS protein] results in increased expression of CYP17A1 mRNA]; Troglitazone inhibits the reaction [[LHB protein co-treated with INS protein] results in increased expression of CYP17A1 protein modified form] CTD PMID:11889176 NCBI chr 6:54,263,574...54,269,286 JBrowse link
G MAPK1 mitogen-activated protein kinase 1 increases phosphorylation
multiple interactions
EXP Troglitazone results in increased phosphorylation of MAPK1 protein
Pioglitazone promotes the reaction [Troglitazone results in increased phosphorylation of MAPK1 protein]
CTD PMID:17065204 NCBI chr14:50,083,079...50,165,528
Ensembl chr14:50,082,896...50,165,523
JBrowse link
G MAPK3 mitogen-activated protein kinase 3 multiple interactions
increases phosphorylation
EXP Pioglitazone promotes the reaction [Troglitazone results in increased phosphorylation of MAPK3 protein] CTD PMID:17065204 NCBI chr 3:18,291,444...18,299,410
Ensembl chr 3:18,291,445...18,299,567
JBrowse link
G PPARG peroxisome proliferator activated receptor gamma multiple interactions
increases activity
EXP 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Troglitazone results in increased activity of PPARG protein]; Troglitazone inhibits the reaction [Pioglitazone results in increased activity of PPARG protein]; Troglitazone promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of PPARG mRNA] CTD PMID:14506076, PMID:17065204, PMID:30481989 NCBI chr13:68,301,566...68,433,951
Ensembl chr13:68,302,655...68,433,947
JBrowse link
G SCARB1 scavenger receptor class B member 1 affects localization EXP Troglitazone affects the localization of SCARB1 protein CTD PMID:16530456 NCBI chr14:28,301,421...28,393,568
Ensembl chr14:28,301,294...28,393,565
JBrowse link
G SPP1 secreted phosphoprotein 1 multiple interactions EXP Troglitazone promotes the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] results in increased expression of SPP1 mRNA] CTD PMID:30481989 NCBI chr 8:131,077,786...131,085,334
Ensembl chr 8:131,077,786...131,085,340
JBrowse link
G TNF tumor necrosis factor multiple interactions EXP [Troglitazone co-treated with Zinc] inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine results in increased activity of TNF protein] CTD PMID:15226458 NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,636...23,703,655
JBrowse link
warfarin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G BMP2 bone morphogenetic protein 2 multiple interactions EXP [TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of BMP2 mRNA; [TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of BMP2 protein; SNAI2 protein promotes the reaction [[TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of BMP2 mRNA] CTD PMID:29358327 NCBI chr17:15,750,487...15,762,982
Ensembl chr17:15,749,835...15,761,215
JBrowse link
G CDKN1A cyclin dependent kinase inhibitor 1A multiple interactions EXP [TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of CDKN1A protein CTD PMID:29358327 NCBI chr 7:32,354,776...32,363,771
Ensembl chr 7:32,359,455...32,363,761
JBrowse link
G EP300 E1A binding protein p300 multiple interactions EXP [TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of EP300 protein CTD PMID:29358327 NCBI chr 5:7,311,165...7,394,515
Ensembl chr 5:7,311,171...7,393,760
JBrowse link
G RUNX2 RUNX family transcription factor 2 multiple interactions EXP [TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of RUNX2 mRNA; [TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of RUNX2 protein; SNAI2 protein promotes the reaction [[TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of RUNX2 mRNA]; SNAI2 protein promotes the reaction [[TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of RUNX2 protein] CTD PMID:29358327 NCBI chr 7:40,106,581...40,353,304
Ensembl chr 7:40,106,513...40,459,686
JBrowse link
G SNAI2 snail family transcriptional repressor 2 multiple interactions EXP [TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of SNAI2 protein; SNAI2 protein promotes the reaction [[TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of BMP2 mRNA]; SNAI2 protein promotes the reaction [[TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of RUNX2 mRNA]; SNAI2 protein promotes the reaction [[TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of RUNX2 protein]; SNAI2 protein promotes the reaction [TP53 protein results in increased susceptibility to Warfarin]; Warfarin promotes the reaction [TP53 protein binds to SNAI2 promoter] CTD PMID:29358327 NCBI chr 4:79,264,880...79,268,475
Ensembl chr 4:79,264,878...79,268,475
JBrowse link
G TP53 tumor protein p53 increases response to substance
increases expression
multiple interactions
EXP TP53 protein results in increased susceptibility to Warfarin
Warfarin results in increased expression of TP53 mRNA
[TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of BMP2 mRNA; [TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of BMP2 protein; [TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of CDKN1A protein; [TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of EP300 protein; [TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of RUNX2 mRNA; [TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of RUNX2 protein; [TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of SNAI2 protein; SNAI2 protein promotes the reaction [[TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of BMP2 mRNA]; SNAI2 protein promotes the reaction [[TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of RUNX2 mRNA]; SNAI2 protein promotes the reaction [[TP53 protein results in increased susceptibility to Warfarin] which results in increased expression of RUNX2 protein]; SNAI2 protein promotes the reaction [TP53 protein results in increased susceptibility to Warfarin]; Warfarin promotes the reaction [TP53 protein binds to SNAI2 promoter]; Warfarin results in increased expression of and results in decreased acetylation of TP53 protein
CTD PMID:29358327 NCBI chr12:52,939,643...52,953,786
Ensembl chr12:52,939,643...52,953,819
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 858
    role 836
      application 473
        pharmaceutical 418
          drug 418
            hematologic agent 43
              2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine 0
              2-O-acetyl-1-O-octadecyl-sn-glycero-3-phosphocholine 0
              6-aminohexanoic acid + 0
              S-nitroso-L-cysteine + 0
              alginic acid 0
              anticoagulant + 40
              argipressin 0
              dermatan sulfate 5
              platelet aggregation inhibitor + 23
              poly(vinylpyrrolidone) + 0
              sodium alginate 0
              ticlopidine + 0
              tranexamic acid 0
paths to the root

NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.